Company Overview
Bionano Genomics, Inc. operates as a provider of genome analysis solutions serving markets across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, offering specialized software that enables genomics laboratories to analyze and interpret data across various platforms. The company is situated within the Healthcare sector, specifically functioning in the Medical Instruments & Supplies industry, which implies a focus on critical diagnostic and research infrastructure rather than direct consumer pharmaceuticals. At the time of this analysis, the company possesses a market capitalization of $12.87M and reported annual revenue of $28.51M, while the specific employee count is listed as N/A. These valuation and revenue figures indicate that Bionano Genomics is a relatively small-cap entity with a modest revenue stream, suggesting a niche position in the broader healthcare instrumentation landscape where growth potential may be significant but current scale remains limited.
Financial Health
The company reported a trailing twelve-month revenue of $28.51M, yet generated a net income of -$26,395,000 and an EBITDA of -$23,812,000, revealing a substantial gap between top-line sales and bottom-line profitability that points to a cost structure where expenses significantly outpace gross margins. This negative free cash flow of -$4,575,125 indicates that the company is currently burning cash, which limits its financial flexibility and reliance on external capital sources to fund operations and research. When analyzing the margins, the gross margin stands at 46.2%, while the operating margin is sharply negative at -107.4% and the profit margin is -92.6%, indicating that operating expenses are more than double the gross revenue generated. The balance sheet shows a cash position of $19.27M against total debt of $16.89M, resulting in a debt-to-equity ratio of 38.03, which suggests a leveraged balance sheet despite the absolute cash holding. Short-term liquidity appears manageable given a current ratio of 1.98, which implies the company holds nearly twice the amount of current assets relative to its current liabilities. However, the return on equity of -66.2% and return on assets of -27.7% reveal that management effectiveness in generating profit from shareholder equity and total assets is currently negative, reflecting the challenges of scaling a pre-profitability biotech or medtech model.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of net income, while the forward P/E is listed as -1.14, a metric that implies expected earnings are still negative and precludes traditional earnings-based valuation comparisons. The price-to-book ratio is 0.28, indicating that the market values the company at a significant discount to its book value, which often occurs in loss-making firms with tangible assets but intangible value potential. Alternative valuation metrics such as the price-to-sales ratio of 0.45 and an EV/EBITDA of -0.44 suggest the market is pricing the stock based on revenue multiple or asset value rather than earnings power, as negative earnings prevent standard profitability multiples from being applied. The stock has traded between a 52-week high of $5.50 and a 52-week low of $1.06, meaning the current price sits well below the recent high, reflecting market skepticism regarding near-term earnings turnaround. With a beta of 1.72, the stock exhibits high price volatility relative to the broader market, moving more than 70% more aggressively than the index during periods of market fluctuation.
Growth & Income
The company experienced a revenue growth rate of -2.6% year-over-year, while earnings growth is N/A due to continued losses, indicating that the company is shrinking in revenue and failing to achieve profitability simultaneously. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders, instead reinvesting its remaining liquidity into operations and potentially R&D to address its negative earnings trajectory. The overall growth and income profile is characterized by negative revenue momentum and a complete absence of dividend income, positioning the investment as a speculative play on future operational improvements rather than a current income or growth vehicle. This profile suggests the asset carries significant risk as the firm attempts to transition from a cash-burning state to a profitable one without providing a safety net of dividends or consistent revenue expansion.